This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Open-Label Study of ARD-0403 in Testosterone Deficient Men (ARD-0403-010)

This study has been terminated.
(Company strategic decision)
Information provided by:
Ardana Bioscience Ltd Identifier:
First received: November 21, 2007
Last updated: March 28, 2008
Last verified: March 2008
November 21, 2007
March 28, 2008
October 2007
Not Provided
Efficacy [ Time Frame: Study Duration ]
Same as current
Complete list of historical versions of study NCT00562731 on Archive Site
Safety and Tolerability [ Time Frame: Study Duration ]
Same as current
Not Provided
Not Provided
Open-Label Study of ARD-0403 in Testosterone Deficient Men
A Phase III, Open-Label Follow-on Study for Long-Term Safety and Efficacy of Testosterone Cream, in Testosterone Deficinet Men Completing Study ARD-0403-004
Male hypogonadism, a disorder associated with testosterone deficiency, is frequently seen in clinical practice and has significant effects on patient well-being. The purpose of this study is to investigate the efficacy and safety of ARD-0403 as a testosterone replacement therapy in testosterone deficient men.
Not Provided
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Drug: ARD-0403
Daily transdermal ARD-0403
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
June 2008
Not Provided

Inclusion Criteria:

  • Testosterone deficiency
  • Completed study ARD-0403-004

Exclusion Criteria:

  • Previous treatment with testosterone replacement therapy within 4 weeks
  • Moderate-severe benign prostatic hypertrophy or prostatic cancer
  • Haematocrit >50%
Sexes Eligible for Study: Male
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
Ardana Bioscience Ltd
Not Provided
Principal Investigator: R Swerdloff University of California, Los Angeles
Ardana Bioscience Ltd
March 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP